drugset
drugset / Trial / NCT05799183

A SHR-1210 BE Study on Healthy Subjects

NCT05799183 ↗

Phase 1 Terminated 12 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to assess the bioequivalence of SHR-1210 before and after process changes.

Timeline

Start
2023-07-04
Primary completion
2023-10-12
Completion
2023-10-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 20 mg —

Indications

No indication recorded.